FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Kung

Research Profile

Living Beings

Anatomy

Physiology

Procedures

Chemicals & Drugs

Disorders

Acute Myeloid Leukemia

Co-author Network

Publications

TOP 3
Brian D Crompton; Jinyan Du; Mark D Fleming; Nancy E Kohl; Andrew L Kung; Miguel N Rivera; Monica L Calicchio; Anne L Carlton; Amanda L Christie; Aaron R Thorner; Kimberly Stegmaier
High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma.
Julia Etchin; Michael Kauffman; Alex Kentsis; Andrew L Kung; Bonnie T Le; Anthony Letai; Marc R Mansour; Dilara McCauley; Joan Montero; Scott J Rodig; Takaomi Sanda; Sharon Shacham; Richard Stone; Amanda L Christie; A Thomas Look
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Andrei V Krivtsov; Andrew L Kung; A M Melnick; Amit Sinha; Matthew C Stubbs; P J M Valk; L Bullinger; Ruud Delwel; K Döhner; Z Feng; M E Figueroa; Scott A Armstrong
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Kung (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Brian D Crompton; Jinyan Du; Mark D Fleming; Nancy E Kohl; Andrew L Kung; Miguel N Rivera; Monica L Calicchio; Anne L Carlton; Amanda L Christie; Aaron R Thorner; Kimberly Stegmaier
High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma.
Cancer research 2013;73(9):2873-83.
2013: Julia Etchin; Michael Kauffman; Alex Kentsis; Andrew L Kung; Bonnie T Le; Anthony Letai; Marc R Mansour; Dilara McCauley; Joan Montero; Scott J Rodig; Takaomi Sanda; Sharon Shacham; Richard Stone; Amanda L Christie; A Thomas Look
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
British journal of haematology 2013;161(1):117-27.
2013: Andrei V Krivtsov; Andrew L Kung; A M Melnick; Amit Sinha; Matthew C Stubbs; P J M Valk; L Bullinger; Ruud Delwel; K Döhner; Z Feng; M E Figueroa; Scott A Armstrong
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
Leukemia 2013;27(4):852-60.
2013: Rizwan Haq; Aeron D Hurley; Andrew L Kung; Abhinav Nellore; Glenn C Rowe; Jonathan Shoag; Jun S Song; Jennifer A Wargo; Pedro Andreu-Perez; Zoltan Arany; Hannah Edelman; David E Fisher; Dennie T Frederick; Satoru Yokoyama; Hans R Widlund
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
Cancer cell 2013;23(3):302-15.
2013: Giovanni Roti; Angela H Su; Jon C Aster; Stephen C Blacklow; Anne Carlton; Andrew L Kung; Michele Markstein; Kostandin Pajcini; Warren S Pear; Norbert Perrimon; Kenneth N Ross; Kimberly Stegmaier
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.
Cancer cell 2013;23(3):390-405.
2013: Alexandre Puissant; Jun Qi; William A Weiss; Rhamy Zeid; Gabriela Alexe; Christopher F Bassil; Cyril H Benes; James E Bradner; Yvan H Chanthery; Stacey M Frumm; Matthew J Garnett; Patricia Greninger; William Clay Gustafson; Andrew L Kung; Ultan McDermott; Erin A Nekritz; Kimberly Stegmaier
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Cancer discovery 2013;3(3):308-23.
2013: J Etchin; A Farmer; M Kauffman; Alex Kentsis; Andrew L Kung; M R Mansour; D McCauley; S J Rodig; T Sanda; Sharon Shacham; Q Sun; Z C Zhang; C Barcelo; Y M Chook; A L Christie; A Thomas Look
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Leukemia 2013;27(1):66-74.
2012: Yoon Jong Choi; Amanda L Christie; Per Hydbring; Andrew L Kung; Xiaoyu Li; A Thomas Look; Takaomi Sanda; Sabina Signoretti; Joanna Stefano; Harald von Boehmer; Piotr Sicinski
The requirement for cyclin D function in tumor maintenance.
Cancer cell 2012;22(4):438-51.
2012: Christopher J Ott; Ronald M Paranal; Jun Qi; Scott Rodig; Liat Bird; Teresa Bowman; James E Bradner; Nadja Kopp; Andrew L Kung; David M Weinstock
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Blood 2012;120(14):2843-52.
2012: Ellen Weisberg; Z Zhao; R Bronson; A L Christie; J F Daley; Ilene Galinsky; James D Griffin; W Hur; Andrew L Kung; Q Liu; Constantine S Mitsiades; Erik Nelson; T Sanda; Martin Sattler; R Smith; Richard M Stone; N Gray
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Leukemia 2012;26(10):2233-44.
2012: Jen-Chieh Tseng; Yuchuan Wang; Pallab Banerjee; Andrew L Kung
Incongruity of imaging using fluorescent 2-DG conjugates compared to 18F-FDG in preclinical cancer models.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2012;14(5):553-60.
2012: Jen-Chieh Tseng; Andrew L Kung
In vivo imaging of inflammatory phagocytes.
Chemistry & biology 2012;19(9):1199-209.
2012: Kohichi Takada; Loren D Walensky; Wenqing Xu; Jian-Jun Zhao; Di Zhu; Gregory H Bird; Daniel E Carrasco; Mariateresa Fulciniti; David Horst; Andrew L Kung; Madeleine Lemieux; Mala Mani; Nikhil C Munshi; Jeremy Ryan; Ramesh A Shivdasani; Kumar Sukhdeo; Daniel Ruben Carrasco
Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
Science translational medicine 2012;4(148):148ra117.
2012: Erik A Nelson; Maria Nicolais; Richard M Stone; Sarah R Walker; Ellen Weisberg; Michael Xiang; Michal Bar-Natan; Rosemary Barrett; Amanda L Christie; James D Griffin; Surender Kharbanda; Andrew L Kung; Suiyang Liu; David A Frank
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
Genes & cancer 2012;3(7-8):503-11.
2012: Alex Kentsis; Andrew L Kung; Jeffery L Kutok; Jonathan D Licht; Richard J Byers; James G Christensen; Amanda Christie; Suzanne E Dahlberg; Ruud Delwel; Lisa A Moreau; Vu Ngo; Casie Reed; Kim L Rice; Scott J Rodig; Takaomi Sanda; Louis M Staudt; Eleni Tholouli; Peter J M Valk; George Vande Woude; A Thomas Look
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
Nature medicine 2012;18(7):1118-22.
2012: Abdel Kareem Azab; Feda Azab; Ruben D Carrasco; Rana Awwad; Charles P Hart; Jinsong Hu; Andrew L Kung; Charles P Lin; Patricia Maiso; Hai T Ngo; Costas Pitsillides; Phong Quang; Aldo Roccaro; Antonio Sacco; Jessica D Sun; Brian Thompson; Karin Vanderkerken; Irene M Ghobrial
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.
Blood 2012;119(24):5782-94.
2012: James L LaBelle; Chelsea Lawrence; Kenneth Pitter; Michelle L Stewart; Gregory H Bird; Jill K Fisher; Evripidis Gavathiotis; Marina Godes; Samuel G Katz; Andrew L Kung; Loren D Walensky
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.
The Journal of clinical investigation 2012;122(6):2018-31.
2012: Ellen Weisberg; Andrew L Kung; P W Manley; A K Azab; R Bronson; A L Christie; I M Ghobrial; James D Griffin
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
Leukemia 2012;26(5):985-90.
2012: Guo Wei; Rameen Beroukhim; Emily Brown; Lisa Cucolo; Leila Haery; Bina Julian; Andrew L Kung; Adam A Margolin; Shyemaa Shehata; Todd R Golub
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency.
Cancer cell 2012;21(4):547-62.
2012: Douglas W McMillin; Kenneth C Anderson; Leutz Buon; Jake E Delmore; Zachary R Hunter; Hannah M Jacobs; Andrew L Kung; Val Monrose; Paul G Richardson; Peter G Smith; Steven P Treon; Jie Yu; Constantine S Mitsiades
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
Molecular cancer therapeutics 2012;11(4):942-51.
2012: Stephanie N Zimmer; Uthra Suresh; Qing Zhou; Ting Zhou; Alexander bishop; Yidong Chen; Claudia Day; Bijal P Karia; Marsha C Kinney; Andrew L Kung; Madeleine E Lemieux; Vivienne Rebel
Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm.
Experimental hematology 2012;40(4):295-306.e5.
2012: Zhao Chen; Katherine Cheng; Lucian R Chirieac; Daniel B Costa; George D Demetri; Hiromichi Ebi; Jeffrey A Engelman; Yoko Franchetti; Peng Gao; D Neil Hayes; David Jackman; Pasi A Jänne; Andrew L Kung; Charles Lee; Carrie B Lee; Jie Li; Yan Liu; Yuji Nakada; Mizuki Nishino; Jing Ouyang; Pier Paolo Pandolfi; Christopher G Peña; Patrick J Roberts; Amy Saur; Norman E Sharpless; Takeshi Shimamura; Yanping Sun; Tanya Tupper; Zandra Walton; Shumei Wang; Yuchuan Wang; Matthew D Wilkerson; Abigail Altabef; Nabeel Bardeesy; Mohit Butaney; Michael D Cameron; Lewis C Cantley; Diego H Castrillon; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Catherine Yao; Kwok-Kin Wong
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Nature 2012;483(7391):613-7.
2012: Loredana Santo; Tyler Scullen; David Tamang; Jen-Chieh Tseng; John H van Duzer; Min Yang; Scott Rodig; Kenneth C Anderson; James E Bradner; Miriam Canavese; Diana Cirstea; Homare Eda; Teru Hideshima; Matthew Jarpe; Simon S Jones; Andrew L Kung; Ralph Mazitschek; Walter C Ogier; Noopur Raje
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Blood 2012;119(11):2579-89.
2012: Versha Banerji; Kwan T Chow; Daniel J DeAngelo; Stacey M Frumm; Ilene Galinsky; Cynthia K Hahn; William C Hahn; Haig Inguilizian; Rose M Kakoza; Andrew L Kung; Loretta S Li; Kenneth N Ross; Linda Ross; Giovanni Roti; Anna C Schinzel; Gabriela Alexe; Jon C Aster; Richard M Stone; Nicola Tolliday; Kimberly Stegmaier
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.
The Journal of clinical investigation 2012;122(3):935-47.
2012: M M Reddy; E Weisberg; O Abdel-Wahab; A Deshpande; M S Fernandes; J D Griffin; H V Inguilizian; Andrew L Kung; R L Levine; M Sattler
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.
Leukemia 2012;26(3):481-9.
2012: Oliver Weigert; Akinori Yoda; Fabienne Baffert; Liat Bird; James E Bradner; Bjoern Chapuy; Amanda L Christie; Alain De Pover; Nicolas Ebel; Michael J Eck; Dirk Erdmann; Emeline Evrot; Christoph Gaul; Francesco Hofmann; Nadja Kopp; Andrew L Kung; Andrew A Lane; Ross L Levine; Sachie Marubayashi; Michael McKeown; Masato Murakami; Ronald M Paranal; Thomas Radimerski; Catherine H Régnier; Vincent Romanet; Stephen E Sallan; Ralph Tiedt; Angela V Toms; Diederik van Bodegom; Eric Vangrevelinghe; David M Weinstock
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
The Journal of experimental medicine 2012;209(2):259-73.
2012: Abdel Kareem Azab; Feda Azab; Ruben Carrasco; Triona Chonghaile; Ludmila M Flores; Andrew L Kung; Anthony Letai; Charles P Lin; John L Magnani; Patricia Maiso; Val Monrose; Hai T Ngo; John T Patton; Costas Pitsillides; Phong Quang; Aldo Roccaro; Antonio Sacco; Brian Thompson; Irene M Ghobrial
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Blood 2012;119(6):1468-78.
2012: Wei Chong; Marc A deMoya; David R King; Andrew L Kung; Yongqing Li; Baoling Liu; Zhengcai Liu; George C Velmahos; Diane R Wonsey; Ting Zhao; Changmin Chen; Hasan B Alam
Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study.
The journal of trauma and acute care surgery 2012;72(2):347-53; discussion 353-4.
2012: Jen-Chieh Tseng; Mark G McDougall; Hélène A Benink; Isabel Chico-Calero; Andrew L Kung
In Vivo Fluorescent Labeling of Tumor Cells with the HaloTag® Technology.
Current chemical genomics 2012;6():48-54.
2011: Erez Feige; Scott R Granter; Vivien Igras; Mehdi Khaled; Andrew L Kung; Stephen Lee; Carmit Levy; Richard J Lin; Hans R Widlund; Satoru Yokoyama; David E Fisher
Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(43):E924-33.
2011: Hui Xu; Christian M Becker; Amy E Birsner; Ching Yan Chu; Robert J D'Amato; Tina N Davis; Andrew L Kung; Wai Ting Lui; Gene Chi Wai Man; Chi Chiu Wang
Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo.
Fertility and sterility 2011;96(4):1021-8.
2011: Jake E Delmore; Irene M Ghobrial; Timothy Gilpatrick; William C Hahn; Timothy P Heffernan; Ghayas C Issa; Hannah M Jacobs; Efstathios Kastritis; Andrew L Kung; Madeleine E Lemieux; Michael R McKeown; Ronald M Paranal; Jun Qi; Peter B Rahl; Paul G Richardson; Anna C Schinzel; Junwei Shi; Christopher R Vakoc; Richard A Young; Kenneth C Anderson; P Leif Bergsagel; James E Bradner; Marta Chesi; Constantine S Mitsiades
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Cell 2011;146(6):904-17.
2011: Hind Medyouf; Oksana Nemirovsky; Francoise Pflumio; Michael Pollak; Andreas Trumpp; Jen-Chieh Tseng; Carol Wai; Hongfang Wang; Jon C Aster; Joan Carboni; Marco Gottardis; Samuel Gusscott; Martin Holzenberger; Andrew L Kung; Andrew P Weng
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.
The Journal of experimental medicine 2011;208(9):1809-22.
2011: David S Ziegler; Naren Ramakrishna; Sophie E M Veldhuijzen van Zanten; Leigh Zawel; Jessica Barnes; Eva M Fast; Joanna Keating; Santosh kesari; Mark W Kieran; Andrew L Kung
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Neuro-oncology 2011;13(8):820-9.
2011: Deviney Chaponis; Jamie L Dellagatta; Eva Fast; Emily R Greene; Santosh kesari; Andrew L Kung; Dipak Panagrahy; Naren Ramakrishna; Claire Sauvageot; Charles Stiles; Patrick Y Wen; Jessica W Barnes; Mark W Kieran
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Journal of neuro-oncology 2011;104(1):179-89.
2011: James J Cronican; Tina N Davis; Andrew L Kung; Weida Li; Erin M May; Allen F Shih; David B Thompson; Jen-Chieh Tseng; Qiao Zhou; Kevin T Beier; Constance L Cepko; David R Liu
A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo.
Chemistry & biology 2011;18(7):833-8.
2011: Kathrin Maria Bernt; Lars Bullinger; Amanda Daigle; Joerg Faber; Zhaohui Feng; Andrei V Krivtsov; Andrew L Kung; Roy M Pollock; Natalie Punt; Victoria M Richon; Amit Sinha; Sridhar Vempati; Nan Zhu; Scott A Armstrong
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Cancer cell 2011;20(1):66-78.
2011: Scott R Daigle; Lei Jin; L Danielle Johnston; Andrew L Kung; Kevin W Kuntz; Christina R Majer; Mikel P Moyer; Edward J Olhava; Victoria M Richon; Margaret Porter Scott; Jesse J Smith; Christopher J Sneeringer; Jeffrey Song; Carly A Therkelsen; Jen-Chieh Tseng; Yonghong Xiao; Scott A Armstrong; Kathrin Maria Bernt; Richard Chesworth; Robert A Copeland; Roy M Pollock
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Cancer cell 2011;20(1):53-65.
2011: Stephanie N Zimmer; Ruth White; Qing Zhou; Ting Zhou; Sherry L Abboud-Werner; Scott A Armstrong; Ziming Cheng; Diane Horn; Andrei V Krivtsov; Andrew L Kung; Mike Lecocke; David M Livingston; Vivienne Rebel
Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis.
Blood 2011;118(1):69-79.
2011: Brian E Schwartz; Matthias D Hofer; Madeleine E Lemieux; Daniel E Bauer; Michael J Cameron; Nathan H West; Elin S Agoston; Nicolas Reynoird; Saadi Khochbin; Tan Ince; Amanda Christie; Katherine Anne Janeway; Sara O Vargas; Antonio R Perez-Atayde; Jon C Aster; Stephen E Sallan; Andrew L Kung; James E Bradner; Christopher A French
Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Cancer research 2011;71(7):2686-96.
2011: Hiroyuki Inuzuka; Shavali Shaik; Ichiro Onoyama; Daming Gao; Alan Tseng; richard s maser; Bo Zhai; Lixin Wan; Alejandro Gutierrez; Alan W Lau; Yonghong Xiao; Amanda L Christie; Jon Aster; Jeffrey Settleman; Steven P Gygi; Andrew L Kung; Thomas Look; Keiichi I Nakayama; Ronald A DePinho; Wenyi Wei
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.
Nature 2011;471(7336):104-9.
2011: Madeleine E Lemieux; Ziming Cheng; John Cornell; Andrew L Kung; Ruth White; Qing Zhou; Vivienne Rebel
Inactivation of a single copy of Crebbp selectively alters pre-mRNA processing in mouse hematopoietic stem cells.
PloS one 2011;6(8):e24153.
2011: Douglas W McMillin; Chandrasekhar V Miduturu; Joseph Negri; Melissa Ooi; Paul G Richardson; Kenneth C Anderson; Jake Delmore; Nathanael S Gray; Steffen Klippel; Andrew L Kung; Constantine S Mitsiades
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
PloS one 2011;6(7):e20226.
2011: Judith M Runnels; Alicia L Carlson; Costas Pitsillides; Brian Thompson; Juwell Wu; Joel A Spencer; John M J Kohler; AbdelKareem Azab; Anne-Sophie Moreau; Scott Rodig; Andrew L Kung; Kenneth C Anderson; Irene M Ghobrial; Charles P Lin
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.
Journal of biomedical optics 2011;16(1):011006.
2010: Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Selective inhibition of BET bromodomains.
Nature 2010;468(7327):1067-73.
2010: Zhao Chen; Takaaki Sasaki; Xiaohong Tan; Julian Carretero; Takeshi Shimamura; Danan Li; Chunxiao Xu; Yuchuan Wang; Guillaume O Adelmant; Marzia Capelletti; Hyun Joo Lee; Scott J Rodig; Christa Borgman; Seung-Il Park; Hyeong Ryul Kim; Robert F Padera; Jarrod A Marto; Nathanael S Gray; Andrew L Kung; Geoffrey I Shapiro; Pasi A Janne; Kwok-Kin Wong
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
Cancer research 2010;70(23):9827-36.
2010: Ellen Weisberg; Arghya Ray; R Barrett; E Nelson; A L Christie; D Porter; C Straub; Leigh Zawel; J F Daley; S Lazo-Kallanian; Richard M Stone; Ilene Galinsky; D Frank; Andrew L Kung; James D Griffin
Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Leukemia 2010;24(12):2100-9.
2010: Federico Bernal; Mark Wade; Marina Godes; Tina N Davis; David G Whitehead; Andrew L Kung; Geoffrey M Wahl; Loren D Walensky
A stapled p53 helix overcomes HDMX-mediated suppression of p53.
Cancer cell 2010;18(5):411-22.
2010: Ellen Weisberg; Hwan Geun Choi; Rosemary Barrett; Wenjun Zhou; Jianming Zhang; Arghya Ray; Erik A Nelson; Jingrui Jiang; Daisy Moreno; Richard Stone; Ilene Galinsky; Edward Fox; Sophia Adamia; Andrew L Kung; Nathanael S Gray; James D Griffin
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Molecular cancer therapeutics 2010;9(9):2468-77.
2010: Ellen Weisberg; X Deng; H G Choi; R Barrett; Sophia Adamia; A Ray; Daisy Moreno; Andrew L Kung; N Gray; James D Griffin
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.
Leukemia 2010;24(7):1375-8.
2010: Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi A Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood 2010;115(21):4206-16.
2010: Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
Nature medicine 2010;16(4):483-9.
2010: Qing Sheng; Xinggang Liu; Eleanor Fleming; Karen Yuan; Huiying Piao; Jinyun Chen; Zeinab Moustafa; Roman K Thomas; Heidi Greulich; Anna Schinzel; Sara Zaghlul; David Batt; Seth Ettenberg; Matthew Meyerson; Birgit Schoeberl; Andrew L Kung; William C Hahn; Ronny Drapkin; David M Livingston; Joyce F Liu
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
Cancer cell 2010;17(3):298-310.
2009: Erin A Kimbrel; Madeleine E Lemieux; Xiaobo Xia; Tina N Davis; Vivienne Rebel; Andrew L Kung
Systematic in vivo structure-function analysis of p300 in hematopoiesis.
Blood 2009;114(23):4804-12.
2009: Raymond E Moellering; Melanie Cornejo; Tina N Davis; Cristina Del Bianco; Jon C Aster; Stephen C Blacklow; Andrew L Kung; D Gary Gilliland; Gregory L Verdine; James E Bradner
Direct inhibition of the NOTCH transcription factor complex.
Nature 2009;462(7270):182-8.
2009: Cynthia K Hahn; Jacob E Berchuck; Kenneth N Ross; Rose M Kakoza; Karl Clauser; Anna C Schinzel; Linda Ross; Ilene Galinsky; Tina N Davis; Serena J Silver; David E Root; Richard M Stone; Daniel J DeAngelo; Martin Carroll; William C Hahn; Steven A Carr; Todd R Golub; Andrew L Kung; Kimberly Stegmaier
Proteomic and genetic approaches identify Syk as an AML target.
Cancer cell 2009;16(4):281-94.
2009: Dingding Shi; Marius S Pop; Roman Kulikov; Ian M Love; Andrew L Kung; Andrew Kung; Steven R Grossman
CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(38):16275-80.
2009: William Kim; Samanthi Perera; Bing Zhou; Julian Carretero; Jen Jen Yeh; Samuel A Heathcote; Autumn L Jackson; Petros Nikolinakos; Beatriz Ospina; George Naumov; Kathleyn A Brandstetter; Victor J Weigman; Sara Zaghlul; David Hayes; Robert F Padera; John V Heymach; Andrew L Kung; Norman E Sharpless; William G Kaelin; Kwok-Kin Wong
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
The Journal of clinical investigation 2009;119(8):2160-70.
2009: Steven M Corsello; Giovanni Roti; Kenneth N Ross; Kwan T Chow; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone; Andrew L Kung; Todd R Golub; Kimberly Stegmaier
Identification of AML1-ETO modulators by chemical genomics.
Blood 2009;113(24):6193-205.
2009: Erin A Kimbrel; Andrew L Kung
The F-box protein beta-TrCp1/Fbw1a interacts with p300 to enhance beta-catenin transcriptional activity.
The Journal of biological chemistry 2009;284(19):13033-44.
2009: Erin A Kimbrel; Tina N Davis; James E Bradner; Andrew L Kung
In vivo pharmacodynamic imaging of proteasome inhibition.
Molecular imaging 2009;8(3):140-7.
2009: Farzaneh A Sorond; Michele L Shaffer; Andrew L Kung; Lewis A Lipsitz
Desferroxamine infusion increases cerebral blood flow: a potential association with hypoxia-inducible factor-1.
Clinical science (London, England : 1979) 2009;116(10):771-9.
2009: Abdel Kareem Azab; Judith M Runnels; Costas Pitsillides; Anne-Sophie Moreau; Feda Azab; Xavier Leleu; Xiaoying Jia; Renee Wright; Beatriz Ospina; Alicia L Carlson; Clemens Alt; Nicholas Burwick; Aldo Roccaro; Hai T Ngo; Mena Farag; Molly R Melhem; Antonio Sacco; Nikhil C Munshi; Teru Hideshima; Barrett J Rollins; Kenneth C Anderson; Andrew L Kung; Charles P Lin; Irene M Ghobrial
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Blood 2009;113(18):4341-51.
2009: Toshiro Migita; Stacey Ruiz; Alessandro Fornari; Michelangelo Fiorentino; Carmen Priolo; Giorgia Zadra; Fumika Inazuka; Chiara Grisanzio; Emanuele Palescandolo; Eyoung Shin; Christopher Fiore; Wanling Xie; Andrew L Kung; Phillip G Febbo; Aravind Subramanian; Lorelei Mucci; Jing Ma; Sabina Signoretti; Meir Stampfer; William C Hahn; Stephen Finn; Massimo Loda
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
Journal of the National Cancer Institute 2009;101(7):519-32.
2009: Claire Sauvageot; Jessica Leigh Weatherbee; Santosh kesari; Susan Elizabeth Winters; Jessica Barnes; Jamie Dellagatta; Naren Ramakrishna; Charles D Stiles; Andrew L Kung; Mark W Kieran; Patrick Y Wen
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Neuro-oncology 2009;11(2):109-21.
2009: Xiaobo Xia; Madeleine E Lemieux; Wei LI; Jason S Carroll; Myles Brown; X Shirley Liu; Andrew L Kung
Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(11):4260-5.
2009: Joerg Faber; Andrei V Krivtsov; Matthew C Stubbs; Renee Wright; Tina N Davis; Marry van den Heuvel-Eibrink; Christian M Zwaan; Andrew L Kung; Scott A Armstrong
HOXA9 is required for survival in human MLL-rearranged acute leukemias.
Blood 2009;113(11):2375-85.
2009: Jiang Yang; Diane R Bielenberg; Scott J Rodig; Robert Doiron; Matthew C Clifton; Andrew L Kung; Roland K Strong; David Zurakowski; Marsha A Moses
Lipocalin 2 promotes breast cancer progression.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(10):3913-8.
2009: Kimberly Ng; Masayuki Nitta; Lauren Hu; Santosh kesari; Andrew L Kung; Alan D'Andrea; Clark C Chen
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Clinical neurosurgery 2009;56():107-18.
2009: Xiaobo Xia; Andrew L Kung
Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia.
Genome biology 2009;10(10):R113.
2009: Tatiana V Kolesnikova; Alexander R Kazarov; Madeleine E Lemieux; Marc A Lafleur; Santosh kesari; Andrew L Kung; Martin E Hemler
Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo.
Neoplasia (New York, N.Y.) 2009;11(1):77-86, 4p following 86.
2009: Jinyan Du; Paula Bernasconi; Karl R Clauser; D R Mani; Stephen P Finn; Rameen Beroukhim; Melissa Burns; Bina Julian; Xiao P Peng; Haley Hieronymus; Rebecca L Maglathlin; Timothy A Lewis; Linda M Liau; Phioanh Nghiemphu; Ingo K Mellinghoff; David N Louis; Massimo Loda; Steven A Carr; Andrew L Kung; Todd R Golub
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
Nature biotechnology 2009;27(1):77-83.
2008: Ellen Weisberg; Johannes Roesel; Guido Bold; Pascal Furet; Jingrui Jiang; Jan Cools; Renee D Wright; Erik Nelson; Rosemary Barrett; Arghya Ray; Daisy Moreno; Elizabeth Hall-Meyers; Richard Stone; Ilene Galinsky; Edward A Fox; Gary Gilliland; John F Daley; Suzan Lazo-Kallanian; Andrew L Kung; James D Griffin
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Blood 2008;112(13):5161-70.
2008: Andrei V Krivtsov; Zhaohui Feng; Madeleine E Lemieux; Joerg Faber; Sridhar Vempati; Amit Sinha; Xiaobo Xia; Jonathan Jesneck; Adrian P Bracken; Lewis B Silverman; Jeffery L Kutok; Andrew L Kung; Scott A Armstrong
H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Cancer cell 2008;14(5):355-68.
2008: David S Ziegler; Renee D Wright; Santosh kesari; Madeleine E Lemieux; Mary A Tran; Monish Jain; Leigh Zawel; Andrew L Kung
Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.
The Journal of clinical investigation 2008;118(9):3109-22.
2008: Satoru Yokoyama; Erez Feige; Laura L Poling; Carmit Levy; Hans R Widlund; Mehdi Khaled; Andrew L Kung; David E Fisher
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Pigment cell & melanoma research 2008;21(4):457-63.
2008: Cynthia K Hahn; Kenneth N Ross; Ian M Warrington; Ralph Mazitschek; Cindy M Kanegai; Renee D Wright; Andrew L Kung; Todd R Golub; Kimberly Stegmaier
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(28):9751-6.
2008: Junghee Lee; Sean Hagerty; Kerry Cormier; Jinho Kim; Andrew L Kung; Robert J Ferrante; Hoon Ryu
Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation.
Human molecular genetics 2008;17(12):1774-82.
2008: Ellen Weisberg; Renee D Wright; Douglas W McMillin; Constantine S Mitsiades; Arghya Ray; Rosemary Barrett; Sophia Adamia; Richard M Stone; Ilene Galinsky; Andrew L Kung; James D Griffin
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Molecular cancer therapeutics 2008;7(5):1121-9.
2008: Ellen Weisberg; Lolita Banerji; Renee D Wright; Rosemary Barrett; Arghya Ray; Daisy Moreno; Laurence Catley; Jingrui Jiang; Elizabeth Hall-Meyers; Maira Sauveur-Michel; Richard M Stone; Ilene Galinsky; Edward A Fox; Andrew L Kung; James D Griffin
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Blood 2008;111(7):3723-34.
2008: David S Ziegler; Andrew L Kung; Mark W Kieran
Anti-apoptosis mechanisms in malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):493-500.
2008: David S Ziegler; Andrew L Kung
Therapeutic targeting of apoptosis pathways in cancer.
Current opinion in oncology 2008;20(1):97-103.
2008: Matthew C Stubbs; Y M Kim; Andrei V Krivtsov; Renee D Wright; Z Feng; J Agarwal; Andrew L Kung; Scott A Armstrong
MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Leukemia 2008;22(1):66-77.
2007: Ellen Weisberg; Andrew L Kung; Renee D Wright; Daisy Moreno; Laurence Catley; Arghya Ray; Leigh Zawel; Mary Tran; Jan Cools; Gary Gilliland; Constantine S Mitsiades; Douglas W McMillin; Jingrui Jiang; Elizabeth Hall-Meyers; James D Griffin
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Molecular cancer therapeutics 2007;6(7):1951-61.
2007: Kimberly Stegmaier; Jenny S Wong; Kenneth N Ross; Kwan T Chow; David Peck; Renee D Wright; Stephen L Lessnick; Andrew L Kung; Todd R Golub
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
PLoS medicine 2007;4(4):e122.
2007: Yazan Alsayed; Hai T Ngo; Judith M Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; David G Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Blood 2007;109(7):2708-17.
2007: Ellen Weisberg; Laurence Catley; Renee D Wright; Daisy Moreno; Lolita Banerji; Arghya Ray; Paul W Manley; Jürgen Mestan; Doriano Fabbro; Jingrui Jiang; Elizabeth Hall-Meyers; Linda Callahan; Jamie L DellaGatta; Andrew L Kung; James D Griffin
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Blood 2007;109(5):2112-20.
2007: Andrew L Kung
Practices and pitfalls of mouse cancer models in drug discovery.
Advances in cancer research 2007;96():191-212.
2006: Maria Torres-Arzayus; Jing Yuan; Jamie L DellaGatta; Heidi Lane; Andrew L Kung; Myles Brown
Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
Cancer research 2006;66(23):11381-8.
2006: Ellen Weisberg; Renee D Wright; Jingrui Jiang; Arghya Ray; Daisy Moreno; Paul W Manley; Doriano Fabbro; Elizabeth Hall-Meyers; Laurence Catley; klaus podar; Andrew L Kung; James D Griffin
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Gastroenterology 2006;131(6):1734-42.
2006: Navid Redjal; Jennifer A Chan; Rosalind A Segal; Andrew L Kung
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6765-71.
2006: Ian Davis; Jessica J Kim; Fatih Ozsolak; Hans R Widlund; Orit Rozenblatt-Rosen; Scott R Granter; Jinyan Du; Jonathan A Fletcher; Christopher T Denny; Stephen L Lessnick; W Marston Linehan; Andrew L Kung; David E Fisher
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.
Cancer cell 2006;9(6):473-84.
2006: Christian M Becker; Renee D Wright; Ronit Satchi-Fainaro; Tae Funakoshi; Judah Folkman; Andrew L Kung; Robert J D'Amato
A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy.
The American journal of pathology 2006;168(6):2074-84.
2006: Nava Almog; Vanessa Henke; Ludmila Flores; Lynn Hlatky; Andrew L Kung; Renee D Wright; Raanan Berger; Lloyd Hutchinson; George N Naumov; Elise Bender; Lars A Akslen; Eike-Gert Achilles; Judah Folkman
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006;20(7):947-9.
2006: Oszkar Szentirmai; Cheryl H Baker; Ning Lin; Szofia Szucs; Masaya Takahashi; Shigeru Kiryu; Andrew L Kung; Richard C Mulligan; Bob S Carter
Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
Neurosurgery 2006;58(2):365-72; discussion 365-72.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Andrew L Kung; Faith E Davies; Gareth Morgan; Masaharu Akiyama; Reshma Shringarpure; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Neal Rosen; Kenneth C Anderson
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
2005: B Mark Woerner; Nicole M Warrington; Andrew L Kung; Arie Perry; Joshua B Rubin
Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies.
Cancer research 2005;65(24):11392-9.
2005: Yi Tang; Minjung Kim; Daniel Carrasco; Andrew L Kung; Lynda Chin; Ralph Weissleder
In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging.
Cancer research 2005;65(18):8324-30.
2005: Maofu Fu; Chenguang Wang; Mahadev Rao; Xiaofang Wu; Toula Bouras; Xueping Zhang; Zhiping Li; Xuanmao Jiao; Jianguo Yang; Anping Li; Neil D Perkins; Bayar Thimmapaya; Andrew L Kung; Alberto Munoz; Antonio Giordano; Michael P Lisanti; Richard G Pestell
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism.
The Journal of biological chemistry 2005;280(33):29728-42.
2005: Patricia Dahia; Kenneth N Ross; Matthew E Wright; César Y Hayashida; Sandro Santagata; Marta Barontini; Andrew L Kung; Gabriela Sanso; James F Powers; Arthur S Tischler; Richard A Hodin; Shannon Heitritter; Francis Moore; Robert Dluhy; Julie Ann Sosa; I Tolgay Ocal; Diana E Benn; Deborah J Marsh; Bruce G Robinson; Katherine Schneider; Judy E Garber; Seth M Arum; Marta Korbonits; Ashley Grossman; Pascal Pigny; sergio toledo; Vania Nosé; Cheng Li; Charles D Stiles
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas.
PLoS genetics 2005;1(1):72-80.
2005: Chrysi Kanellopoulou; Stefan A Muljo; Andrew L Kung; Shridar Ganesan; Ronny Drapkin; Thomas Jenuwein; David M Livingston; Klaus Rajewsky
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing.
Genes & development 2005;19(4):489-501.
2005: Leila Aminova; Juan C Chavez; Junghee Lee; Hoon Ryu; Andrew L Kung; Joseph C Lamanna; Rajiv R Ratan
Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line.
The Journal of biological chemistry 2005;280(5):3996-4003.
2005: Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian J P Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurence Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer cell 2005;7(2):129-41.
2004: Jean-Pierre Bourquin; Ian Thornley; Donna Neuberg; Lisa Brennan; Andrew L Kung; J Clark; Leslie E Lehmann; Eva C Guinan
Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood.
Bone marrow transplantation 2004;34(9):795-8.
2004: Loren D Walensky; Andrew L Kung; Iris Escher; Thomas J Malia; Scott Barbuto; Renee D Wright; Gerhard Wagner; Gregory L Verdine; Stanley J Korsmeyer
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.
Science (New York, N.Y.) 2004;305(5689):1466-70.
2004: Danielle L Poulin; Andrew L Kung; James A DeCaprio
p53 targets simian virus 40 large T antigen for acetylation by CBP.
Journal of virology 2004;78(15):8245-53.
2004: Andrew L Kung; Sonya D Zabludoff; Dennis Stanley France; Steven J Freedman; Elizabeth A Tanner; Annelisa Vieira; Susan Cornell-Kennon; Jennifer Lee; Beqing Wang; Jamin Wang; Klaus Memmert; Hans-Ulrich Naegeli; Frank Petersen; Michael J Eck; Kenneth W Bair; Alexander W Wood; David M Livingston
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.
Cancer cell 2004;6(1):33-43.
2004: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Reshma Shringarpure; Masaharu Akiyama; Teru Hideshima; Dharminder Chauhan; Marie Joseph; Towia Libermann; Carlos García-Echeverría; Mark A Pearson; Francesco Hofmann; Kenneth C Anderson; Andrew L Kung
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer cell 2004;5(3):221-30.
2003: Joshua B Rubin; Andrew L Kung; Robyn S Klein; Jennifer A Chan; YanPing Sun; Karl Schmidt; Mark W Kieran; Andrew D Luster; Rosalind A Segal
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(23):13513-8.
2003: Michal Safran; William Kim; Andrew L Kung; James W Horner; Ronald A DePinho; William G Kaelin
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination.
Molecular imaging 2003;2(4):297-302.
2003: Steven J Freedman; Zhen-Yu J Sun; Andrew L Kung; Dennis Stanley France; Gerhard Wagner; Michael J Eck
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2.
Nature structural biology 2003;10(7):504-12.
2003: Steven R Grossman; Maria E Deato; Chrystelle Brignone; Ho Man Chan; Andrew L Kung; Hideaki Tagami; Yoshihiro Nakatani; David M Livingston
Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
Science (New York, N.Y.) 2003;300(5617):342-4.
2003: Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Cancer cell 2003;3(2):173-83.
2002: Vivienne Rebel; Andrew L Kung; Elizabeth A Tanner; Hong Yang; Roderick T Bronson; David M Livingston
Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(23):14789-94.
2002: Steven J Freedman; Zhen-Yu J Sun; Florence Poy; Andrew L Kung; David M Livingston; Gerhard Wagner; Michael J Eck
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(8):5367-72.
2001: WT Tse; J Tang; Ou Jin; C Korsgren; KM John; Andrew L Kung; Babette Gwynn; Luanne L Peters; Samuel E Lux
A new spectrin, beta IV, has a major truncated isoform that associates with promyelocytic leukemia protein nuclear bodies and the nuclear matrix.
The Journal of biological chemistry 2001;276(26):23974-85.
2000: Andrew L Kung; S Wang; J M Klco; William G Kaelin; David M Livingston
Suppression of tumor growth through disruption of hypoxia-inducible transcription.
Nature medicine 2000;6(12):1335-40.
2000: Josiane E Eid; Andrew L Kung; Ralph Scully; David M Livingston
p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion.
Cell 2000;102(6):839-48.
2000: James V Falvo; BM Brinkman; Alla V Tsytsykova; Eunice Y Tsai; Tso-Pang Yao; Andrew L Kung; Anne E Goldfeld
A stimulus-specific role for CREB-binding protein (CBP) in T cell receptor-activated tumor necrosis factor alpha gene expression.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(8):3925-9.
2000: Andrew L Kung; Vivienne Rebel; Roderick T Bronson; L E Ch'ng; Colin A Sieff; David M Livingston; Tso-Pang Yao
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.
Genes & development 2000;14(3):272-7.
1999: S Bhattacharya; C L Michels; M K Leung; Z P Arany; Andrew L Kung; David M Livingston
Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1.
Genes & development 1999;13(1):64-75.
1998: Steven R Grossman; M Perez; Andrew L Kung; M Joseph; C Mansur; Z X Xiao; S Kumar; Peter M Howley; David M Livingston
p300/MDM2 complexes participate in MDM2-mediated p53 degradation.
Molecular cell 1998;2(4):405-15.
1994: M G DeWald; R C Sharma; Andrew L Kung; H E Wong; S W Sherwood; R T Schimke
Heterogeneity in the mitotic checkpoint control of BALB/3T3 cells and a correlation with gene amplification propensity.
Cancer research 1994;54(19):5064-70.
1994: R T Schimke; Andrew L Kung; S S Sherwood; J Sheridan; R Sharma
Life, death and genomic change in perturbed cell cycles.
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 1994;345(1313):311-7.
1994: S W Sherwood; D F Rush; Andrew L Kung; R T Schimke
Cyclin B1 expression in HeLa S3 cells studied by flow cytometry.
Experimental cell research 1994;211(2):275-81.
1993: Andrew L Kung; S W Sherwood; R T Schimke
Differences in the regulation of protein synthesis, cyclin B accumulation, and cellular growth in response to the inhibition of DNA synthesis in Chinese hamster ovary and HeLa S3 cells.
The Journal of biological chemistry 1993;268(31):23072-80.
1993: S W Sherwood; Andrew L Kung; J Roitelman; Robert D Simoni; R T Schimke
In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(8):3353-7.
1991: R T Schimke; Andrew L Kung; D F Rush; S W Sherwood
Differences in mitotic control among mammalian cells.
Cold Spring Harbor symposia on quantitative biology 1991;56():417-25.
1990: Andrew L Kung; S W Sherwood; R T Schimke
Cell line-specific differences in the control of cell cycle progression in the absence of mitosis.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(24):9553-7.
1990: Andrew L Kung; A Zetterberg; S W Sherwood; R T Schimke
Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation.
Cancer research 1990;50(22):7307-17.